EUVIMEDEUVIMED entdecken
Crossref

In Silico Design of CT26 Polytope and its Surface Display by ClearColi™-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma

Elham Sharif, Navid Nezafat, Fatemeh Maghsood Ahmadi, Elham Mohit

Applied Biochemistry and Biotechnology · 2024

DOI: 10.1007/s12010-024-04971-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2024. Verfasst von Elham Sharif und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, No. 2660, Vali-e-Asr Ave, Tehran, 199…. Hauptthemen laut MEDLINE: Cancer Vaccines, Colonic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Simultaneous targeting of several mutations can be useful in colorectal cancer (CRC) due to its heterogeneity and presence of somatic mutations. As CT26 mutations and expression profiles resemble those of human CRC, we focused on designing a polyepitope vaccine based on CT26 neoepitopes. Due to its low immunogenicity, outer membrane vesicles (rOMV) as an antigen delivery system and adjuvant was applied. Herein, based on previous experimental and our in silico studies four CT26 neoepitopes with the ability to bind MHC-I and MHC-II, TCR, and induce IFN-α production were selected. To increase their immunogenicity, the gp70 and PADRE epitopes were added. The order of the neoepitopes was determined through 3D structure analysis using ProSA, Verify 3D, ERRAT, and Ramachandran servers. The stable peptide-protein docking between the selected epitopes and MHC alleles strengthen our prediction. The CT26 polytope vaccine sequence was fused to the C-terminal of cytolysin A (ClyA) anchor protein and rOMVs were isolated from endotoxin-free ClearColi™ strain. The results of the C-ImmSim server showed that the ClyA-CT26 polytope vaccine could induce T and B cells immunity.The ClyA-CT26 polytope was characterized as a soluble, stable, immunogen, and non-allergen vaccine and optimized for expression in ClearColi™ 24 h after induction with 1 mM IPTG at 25 °C. Western blot analysis confirmed the expression of ClyA-CT26 polytope by ClearColi™ and also on ClearColi™-derived rOMVs. In conclusion, we found that ClearColi™-derived rOMVs with CT26 polytope can deliver CRC neoantigens and induce antitumor immunity, but in vivo immunological studies are needed to confirm vaccine efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesColonic NeoplasmsAnimalsHumansComputer SimulationMiceEpitopesCell Line, Tumor

Stichwörter der Autor:innen

CT26ClearColi™Colon carcinomaImmunoinformatic analysisNeoepitopeOuter membrane vesicles (OMVs)

Substanzen

Cancer VaccinesEpitopes

Autor:innen und Institutionen

  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, No. 2660, Vali-e-Asr Ave, Tehran, 1991953381, Iran.
  • Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Microbiology North Tehran Branch, Islamic Azad University, Tehran, Iran.
  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, No. 2660, Vali-e-Asr Ave, Tehran, 1991953381, Iran. e.mohit@sbmu.ac.ir.

Förderung

  • Shahid Beheshti University of Medical Sciences

Zitieren

APA

Sharif, E., Nezafat, N., Ahmadi, F. M., & Mohit, E. (2024). In Silico Design of CT26 Polytope and its Surface Display by ClearColi™-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-04971-x

Vancouver

Sharif E, Nezafat N, Ahmadi FM, Mohit E. In Silico Design of CT26 Polytope and its Surface Display by ClearColi™-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma. Applied Biochemistry and Biotechnology. 2024. doi:10.1007/s12010-024-04971-x

BibTeX
@article{Sharif2024,
  author = {Sharif, Elham and Nezafat, Navid and Ahmadi, Fatemeh Maghsood and Mohit, Elham},
  title = {In Silico Design of CT26 Polytope and its Surface Display by ClearColi™-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2024},
  doi = {10.1007/s12010-024-04971-x}
}
Kostenlos starten →